Since its inception in 1992 as part of the Veterans Health Care Act, the 340B Drug Pricing Program has grown into a major fixture of U.S. healthcare procurement. The program enables eligible hospitals—including disproportionate share hospitals, critical access hospitals, and federally qualified health centers—to acquire medications at negotiated rates substantially below average wholesale prices. Over three decades, participation has expanded significantly, with the program now dispensing billions of dollars in discounted medications annually across the United States. Despite its scale and longevity, the 340B program remains a focal point in pharmaceutical pricing debates. Medicare’s newly proposed payment reductions aim to address federal cost concerns, though the initiative has reignited questions about program oversight and accountability mechanisms. Read the full article on GMJ Newsroom.
Was this article helpful?
